BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1275 related articles for article (PubMed ID: 6418767)

  • 1. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil extracellular traps can activate alternative complement pathways.
    Wang H; Wang C; Zhao MH; Chen M
    Clin Exp Immunol; 2015 Sep; 181(3):518-27. PubMed ID: 25963026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gangliosides on activation of the alternative pathway of human complement.
    Michalek MT; Bremer EG; Mold C
    J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
    Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
    Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation by the surface of Plasmodium falciparum infected erythrocytes.
    Stanley HA; Mayes JT; Cooper NR; Reese RT
    Mol Immunol; 1984 Feb; 21(2):145-50. PubMed ID: 6369119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent linkage of C3 to properdin during complement activation.
    Whiteman LY; Purkall DB; Ruddy S
    Eur J Immunol; 1995 May; 25(5):1481-4. PubMed ID: 7774654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.